Citation: | DU Juan, WU Hua, DING Ning, LIU Jia. Effect of recombinant human brain natriuretic peptide combined with furosemide in improvement of cardiac function and blood gas indicators in patients with acute myocardial infarction complicated with heart failure[J]. Journal of Clinical Medicine in Practice, 2024, 28(15): 80-83, 89. DOI: 10.7619/jcmp.20241336 |
To investigate the improvement effect of recombinant human brain natriuretic peptide (rhBNP) combined with furosemide on cardiac function and blood gas indicators in patients with acute myocardial infarction (AMI) complicated with heart failure.
A total of 152 patients with AMI complicated with heart failure were selected and randomly divided into control group and observation group using a random drawing method, with 76 patients in each group. The control group was treated with furosemide, while the observation group received a combination therapy of rhBNP and furosemide. Changes in cardiac function and blood gas indicators before and after treatment were observed in both groups, and the therapeutic effects and adverse reactions during medication were compared.
Cardiac function indicators and arterial blood gas indicators in both groups were significantly improved after treatment compared with those before treatment. Additionally, the left ventricular ejection fraction (LVEF), blood oxygen saturation (SaO2), and partial pressure of oxygen [pa(O2)] levels were higher, while the left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), and partial pressure of carbon dioxide[pa(CO2)]levels were lower in the observation group compared to the control group (P < 0.05). After treatment, the levels of serum creatinine (SCr) and creatine kinase isoenzyme (CK-MB) decreased, and the level of myoglobin (Mb) increased significantly in the observation group, which were better than those in the control group (P < 0.05). The total effective rate of treatment in the observation group was significantly higher than that in the control group (90.79% versus 60.53%, P < 0.05). There was no statistically significant difference in the total incidence of adverse reactions during medication between the two groups (P>0.05).
The clinical treatment of AMI complicated with heart failure using a combination of rhBNP and furosemide has a significant improvement effect on cardiac function and blood gas indicators, with a definitive therapeutic effect and no increase in adverse reactions, thus it is better in safety.
[1] |
赵冬, 杨丽霞, 赵绮旎. 急性心梗流行病学特征及危险因素的调查分析[J]. 实用预防医学, 2022, 29(9): 1124-1126. doi: 10.3969/j.issn.1006-3110.2022.09.025
|
[2] |
马萌雪, 马萍, 徐清斌, 等. 急性心肌梗死并发心力衰竭的风险预测模型构建及验证[J]. 天津医药, 2023, 51(11): 1221-1226. doi: 10.11958/20230055
|
[3] |
李莉. 冻干重组人脑利钠肽治疗心力衰竭的研究进展[J]. 中国处方药, 2020, 18(6): 11-12. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCF202006010.htm
|
[4] |
郝建峰, 李书瑞, 张绍义, 等. 呋塞米静脉点滴治疗心力衰竭基础和临床研究进展[J]. 现代中西医结合杂志, 2014, 23(4): 454-456. doi: 10.3969/j.issn.1008-8849.2014.04.051
|
[5] |
中国医师协会急诊医师分会, 中华医学会心血管病学分会, 中华医学会检验医学分会. 急性冠脉综合征急诊快速诊疗指南[J]. 中华急诊医学杂志, 2016, 25(4): 397-404. doi: 10.3760/cma.j.issn.1671-0282.2016.04.002
|
[6] |
中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 急性心力衰竭基层诊疗指南(实践版·2019)[J]. 中华全科医师杂志, 2019, 18(10): 931-935. doi: 10.3760/cma.j.issn.1671-7368.2019.10.007
|
[7] |
BAHIT M C, KOCHAR A, GRANGER C B. Post-myocardial infarction heart failure[J]. JACC Heart Fail, 2018, 6(3): 179-186. doi: 10.1016/j.jchf.2017.09.015
|
[8] |
KAMON D, SUGAWARA Y, SOEDA T, et al. Predominant subtype of heart failure after acute myocardial infarction is heart failure with non-reduced ejection fraction[J]. ESC Heart Fail, 2021, 8(1): 317-325. doi: 10.1002/ehf2.13070
|
[9] |
于炎武, 蒲博轩, 赫广达, 等. 高敏感格拉斯哥评分与射血分数保留型心力衰竭患者长期预后的关联性分析[J]. 临床心血管病杂志, 2024, 40(1): 64-68. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXB202401012.htm
|
[10] |
王剑. 观察早期应用小剂量多巴胺联合呋塞米治疗心力衰竭的疗效分析[J]. 中国药物与临床, 2020, 20(20): 3429-3431. https://www.cnki.com.cn/Article/CJFDTOTAL-YWLC202020034.htm
|
[11] |
刘晓晨. 静脉微量泵入大剂量呋塞米治疗心力衰竭的效果研究[J]. 中国现代药物应用, 2022, 16(11): 89-91. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWYY202211021.htm
|
[12] |
杜培俊. 冻干重组人脑利钠肽在急性心力衰竭治疗中的应用[J]. 中国药物与临床, 2020, 20(24): 4101-4102. https://www.cnki.com.cn/Article/CJFDTOTAL-YWLC202024021.htm
|
[13] |
陈婷婷, 吴凤家, 蒋行兰, 等. 新活素对绝经后心衰患者疗效心功能及雌激素水平的影响[J]. 中国妇幼保健, 2023, 38(9): 1574-1577. https://www.cnki.com.cn/Article/CJFDTOTAL-ZFYB202309006.htm
|
[14] |
杨明, 李鲲鹏, 宋书田, 等. 重组人脑利钠肽调控丝裂原活化蛋白激酶信号通路减轻心肌缺血再灌注损伤的作用及机制[J]. 华西医学, 2022, 37(10): 1538-1544. https://www.cnki.com.cn/Article/CJFDTOTAL-HXYX202210017.htm
|
[15] |
任艳艳. 重组人脑利钠肽+呋塞米治疗急性左心衰的效果和对心功能的影响评价[J]. 中国国境卫生检疫杂志, 2023, 46(S02): 188-189. https://www.cnki.com.cn/Article/CJFDTOTAL-HAIN202416006.htm
|
[16] |
雷芾华, 牛敏瑞, 陈金荣. 新活素序贯诺欣妥治疗心力衰竭有效性及安全性meta分析[J]. 新疆医科大学学报, 2023, 46(1): 108-116. https://www.cnki.com.cn/Article/CJFDTOTAL-XJYY202301018.htm
|
1. |
杨栋梁. 高压氧联合经鼻持续气道正压通气在阻塞性睡眠呼吸暂停低通气综合征患者中的应用效果. 医疗装备. 2024(04): 71-74 .
![]() | |
2. |
靳美娜,魏翠英. 慢性间歇低氧-复氧条件下SD大鼠糖代谢水平和体质量的变化. 内蒙古医学杂志. 2024(12): 1409-1413+1418 .
![]() | |
3. |
项蕊,郭智慧,李会,褚鹿鹿,陈颖,李秋云. 基于微信平台的同伴教育护理模式对糖尿病患者疗效分析. 实用临床医药杂志. 2023(05): 134-137 .
![]() | |
4. |
高璐阳,黄志华,罗勤,赵智慧,赵青,柳志红. 钠-葡萄糖协同转运蛋白2抑制剂治疗阻塞性睡眠呼吸暂停的研究进展. 实用临床医药杂志. 2023(07): 133-137 .
![]() | |
5. |
莫汝锋,陈效强,杨永杰. 羧甲司坦联合孟鲁司特钠辅助高压氧疗治疗阻塞性睡眠呼吸暂停低通气综合征的疗效及对患者氧化应激、通气指数的影响. 现代医学与健康研究电子杂志. 2023(22): 49-51 .
![]() |